Allergan entered into a clinical trial agreement with Novartis to conduct a phase 2b study of Allergan's cenicriviroc and Novartis' lead FXR agonist in treating non-alcoholic steatohepatitis.
Here's what you should know.
1. The study will assess the safety, efficacy and tolerability of the joint therapy approach for NASH.
2. NASH is the fastest growing cause of liver cancer and liver transplants in the United States.
3. Allergan did not disclose terms of the deal.
4. There are currently no treatments for NASH.